In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

Could he see more chosen before him as his wait extends into Saturday ... of the Titans' eye in the lead-up to the 2025 NFL Draft after he starred in his lone season with the Hurricanes.

“My mom never got justice from her work acquaintance who attempted to take her life when she was the mother of 3 young kids—years before I was born. She has always credited her beating heart ...

Bre'Andrea Wiley, 19, vanished in January 2022, just weeks before she was scheduled to serve ... but why did the system wait so long to stop this man? After years of reporting his erratic behavior ...

A big question remains in the minds of people: for more benefits, should watermelon be eaten before or after eating food? Morning is the best time to eat watermelon. Eating it for breakfast on an ...

The Ministry of Food and Drug Safety noted on the 24th that it will approve the use of the systemic Myasthenia Gravis treatment, Listigoju (Rozanolixizumab). Myasthenia Gravis is a rare disease ...

"Kings don't concern themselves with opinions of peasants," James wrote after the rapper's remarks Michael Buckner/Variety via Getty; Cindy Ord/Getty LeBron James seemingly clapped back after ...

Shares of Tesla were up nearly 6% at $251.41 in early trading Wednesday, amid broader market gains after comments from President Trump eased worries about tariffs and Federal Reserve independence.

Worries over Fed independence and U.S.-China trade relations both appear to be easing. But don’t look for an “all-clear” in the stock market yet, says our call of the day from Thomas Kee ...